Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“Active surveillance is effective in patients with stage I NSGCT.
In a 457-patient cohort (median FU: 65.3 months), 20% relapsed, but >90% were cured with salvage therapy.
20-year OS: 98.25%.
VI was the strongest predictor of recurrence.”
Authors: Jorge Martínez-Cedillo et al.
